Vertex Pharmaceuticals (VRTX) Change in Accured Expenses (2009 - 2026)
Vertex Pharmaceuticals (VRTX) posted quarterly Change in Accured Expenses of $23.1 million for Q1 2026, down 51.98% year-over-year from $48.1 million in Q1 2025, and up 114.47% quarter-over-quarter from -$159.6 million in Q4 2025.
Vertex Pharmaceuticals (VRTX) Change in Accured Expenses (2009 - 2026) Analysis & Trends
Vertex Pharmaceuticals' Change in Accured Expenses history runs 18 years deep, the most recent figure standing at $23.1 million for Q1 2026.
- In Q1 2026, Change in Accured Expenses fell 51.98% year-over-year to $23.1 million; the TTM figure through Mar 2026 stood at -$141.9 million (down 77.82% YoY), while the FY2025 annual figure was -$116.9 million, down 394.46% from the prior year.
- Change in Accured Expenses for Q1 2026 stood at $23.1 million, up from -$159.6 million in the prior quarter.
- The five-year high for Change in Accured Expenses was $668.3 million in Q3 2023, with the low at -$587.8 million in Q3 2022.
- The 5-year median for Change in Accured Expenses is $61.6 million (2022), against an average of $41.0 million.
- Peak annual rise in Change in Accured Expenses reached 994.11% in 2022, while the deepest fall reached 2659.62% in 2022.
- Vertex Pharmaceuticals' Change in Accured Expenses stood at $583.2 million in 2022, then sank by 198.97% to -$577.2 million in 2023, then increased by 14.54% to -$493.3 million in 2024, then surged by 67.65% to -$159.6 million in 2025, then surged by 114.47% to $23.1 million in 2026.
- Business Quant data shows VRTX's Change in Accured Expenses at $23.1 million in Q1 2026, -$159.6 million in Q4 2025, and -$172.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 222.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 492.70 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 55.78 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 212.44 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 61.62 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 68.82 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | -13.91 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 222.50 Mn |
| Jun 30, 2026 | 222.50 Mn |
| Mar 31, 2026 | 23.10 Mn |
| Mar 31, 2026 | 23.10 Mn |
| Dec 31, 2025 | -159.60 Mn |
| Dec 31, 2025 | -159.60 Mn |
| Sep 30, 2025 | -172.00 Mn |
| Sep 30, 2025 | -172.00 Mn |
| Jun 30, 2025 | 166.60 Mn |
| Jun 30, 2025 | 166.60 Mn |
| Mar 31, 2025 | 48.10 Mn |
| Mar 31, 2025 | 48.10 Mn |
| Dec 31, 2024 | -493.30 Mn |
| Dec 31, 2024 | -493.30 Mn |
| Sep 30, 2024 | 170.60 Mn |
| Sep 30, 2024 | 170.60 Mn |
| Jun 30, 2024 | 194.80 Mn |
| Jun 30, 2024 | 194.80 Mn |
| Mar 31, 2024 | 167.60 Mn |
| Mar 31, 2024 | 167.60 Mn |